Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (253)	10/1/2013 8:11:49 AM
From: pgo-neil	Respond to of 254

4211 continues to do well in trials. This one is for T2 and renal impairment... which sounds like a tougher, more needy pop. Despite the Govt. shutdown and market impact, the pre-market likes this announcement. Up 28% and share price over $3.00. Best, graham -- THE WOODLANDS, Texas, Oct. 1, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. ( LXRX) announced today that LX4211, a first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), successfully met the primary endpoint of reducing post-prandial glucose, in a study of patients with type 2 diabetes and moderate to severe renal impairment. Reducing elevated post-prandial glucose, high blood sugar levels after meals, is a key objective of diabetes therapy. In a placebo-controlled, proof-of-concept study, LX4211 provided clinically meaningful and statistically significant reductions (p2. LX4211 also produced significant elevations in GLP-1, a hormone involved in control of glucose and appetite. Renal impairment occurs in approximately 30% of patients with type 2 diabetes and represents a major unmet medical need with limited treatment options. LX4211's inhibition of SGLT1 in the gastrointestinal (GI) tract, reducing glucose absorption and triggering GLP-1 secretion, offers the potential for treating this medically challenging population with compromised kidney function. In previous Phase 2 studies, LX4211 improved glycemic control in patients with type 2 diabetes with normal renal function. "Our hypothesis was that LX4211 would improve glycemic control even in patients with the greatest degree of renal impairment due to its inhibition of SGLT1 in the GI tract," said Pablo Lapuerta, M.D., Lexicon's chief medical officer. "The post-prandial glucose reductions and GLP-1 elevations observed in this study population support the rationale for demonstrating effective HbA1c reduction in a larger, longer-term Phase 3 trial, and provide further support for the clinical differentiation of LX4211 as a first-in-class dual SGLT1 and SGLT2 inhibitor." In this multicenter study, 30 patients with poorly controlled type 2 diabetes and moderate to severe renal impairment were randomized to either placebo or a 400 mg dose of investigational drug LX4211 taken orally once per day before breakfast. Patients' post-prandial glucose was measured after a standardized meal both at baseline before treatment and after one week of therapy. In addition to achieving the primary efficacy objective of post-prandial glucose reduction, there were no serious adverse events observed in the study and no discontinuations of LX4211 due to adverse events. Lexicon plans to present full results of the study at scientific congresses in 2014.